- Home
- ZBIO vs MBX Comparison
ZBIO vs MBX Comparison
Compare ZBIO & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- MBX
- Stock Information
- Founded
- ZBIO 2019
- MBX 2018
- Country
- ZBIO United States
- MBX United States
- Employees
- ZBIO N/A
- MBX N/A
- Industry
- ZBIO
- MBX
- Sector
- ZBIO
- MBX
- Exchange
- ZBIO NYSE
- MBX NYSE
- Market Cap
- ZBIO 389.2M
- MBX 379.7M
- IPO Year
- ZBIO 2024
- MBX 2024
- Fundamental
- Price
- ZBIO $10.19
- MBX $11.91
- Analyst Decision
- ZBIO Strong Buy
- MBX Strong Buy
- Analyst Count
- ZBIO 7
- MBX 5
- Target Price
- ZBIO $32.29
- MBX $37.40
- AVG Volume (30 Days)
- ZBIO 207.1K
- MBX 243.5K
- Earning Date
- ZBIO 08-16-2025
- MBX 08-16-2025
- Dividend Yield
- ZBIO N/A
- MBX N/A
- EPS Growth
- ZBIO N/A
- MBX N/A
- EPS
- ZBIO N/A
- MBX N/A
- Revenue
- ZBIO $15,000,000.00
- MBX N/A
- Revenue This Year
- ZBIO $206.00
- MBX N/A
- Revenue Next Year
- ZBIO $41.92
- MBX N/A
- P/E Ratio
- ZBIO N/A
- MBX N/A
- Revenue Growth
- ZBIO N/A
- MBX N/A
- 52 Week Low
- ZBIO $5.83
- MBX $4.81
- 52 Week High
- ZBIO $26.25
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- MBX N/A
- Support Level
- ZBIO N/A
- MBX N/A
- Resistance Level
- ZBIO N/A
- MBX N/A
- Average True Range (ATR)
- ZBIO 0.00
- MBX 0.00
- MACD
- ZBIO 0.00
- MBX 0.00
- Stochastic Oscillator
- ZBIO 0.00
- MBX 0.00
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.